Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies
Organizer(s): Christian Klein, Mark S. Cragg and Germaine FuhDate: April 07 - 11, 2019
Location: Beaver Run Resort, Breckenridge, CO, USA
Over the last 20 years, recombinant antibodies have been established into clinical practice for the treatment of diseases ranging from cancer, to autoimmune and infectious diseases. While the first approved antibodies were native IgG antibodies, in recent years the field has rapidly advanced and therapeutic antibodies in preclinical and clinical development now include many non-canonical formats including Fc- engineered antibodies, antibody drug conjugates, bispecific antibodies and antibody-like scaffolds. This Keystone Symposia conference aims to bring together experts in antibody therapeutics, engineering and mechanisms of action from industry and academia to discuss and review the state-of-the-art in the field and discuss their future potential. The conference will foster cross-fertilization between different engineering technologies and scientists from different therapeutic areas. This conference can also help to initiate collaboration on the development of state-of-the-art antibody therapies with the aim to improve therapeutic options for patients. For trainees and early career researchers, this conference provides an opportunity to gain insight into various aspects of therapeutic antibodies and to discuss their projects and ideas face-to-face with experts in the field. A unique component to this conference that distinguishes it from other more commercial meetings in the field, is that this conference will include presentation and discussion of novel/unpublished data.
Scholarship Deadline: December 11 2018
Discounted Abstract Deadline: December 11 2018
Abstract Deadline: January 9 2019
Discounted Registration Deadline: February 6 2019
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
CytomX Therapeutics, Inc.
Denali Therapeutics Inc.
Regeneron Pharmaceuticals, Inc.
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI145248-01
Funding for this conference was made possible (in part) by 1R13AI145248-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.